Your session is about to expire
← Back to Search
Daratumumab + Lenalidomide for Multiple Myeloma (AURIGA Trial)
AURIGA Trial Summary
This trial is testing whether adding daratumumab to lenalidomide can help people with newly diagnosed multiple myeloma who are positive for MRD (as determined by next generation sequencing).
AURIGA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAURIGA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 498 Patients • NCT02136134AURIGA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a known history of testing positive for HIV, hepatitis B, or hepatitis C, unless you have been vaccinated for hepatitis B or have successfully cleared hepatitis C virus from your body.I have remaining cancer cells detected by a specific blood test.I have had moderate to severe asthma in the last 2 years or currently have uncontrolled asthma.I was diagnosed with multiple myeloma, had 4+ treatment cycles, a stem cell transplant within a year of starting treatment, and it's been less than 6 months since my transplant.I have not had Daratumumab or similar treatments, recent radiation (except for symptom relief), or plasmapheresis in the last 28 days.My multiple myeloma has not worsened during any previous treatments.I have COPD with less than half the normal lung function.I have bone marrow samples or MRD test results from before my treatment.I had cancer other than multiple myeloma, treated and cleared over 2 years ago, with no current signs of disease.I am able to care for myself and perform daily activities.My myeloma treatment has been very effective according to IMWG 2016 criteria.My multiple myeloma is affecting my brain or spinal cord.
- Group 1: Daratumumab + Lenalidomide
- Group 2: Lenalidomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the most common issues that Daratumumab has been shown to help with?
"Daratumumab is often used to treat chronic lymphocytic leukemia. Additionally, this medication can be employed for other purposes such as immunomodulation and amyloidosis in patients that have already tried two different systemic chemotherapy regimens."
Is this trial taking place at multiple research facilities across the United States?
"This study is being conducted at Franciscan Health in Indianapolis, Indiana; NYU Winthrop in Mineola, New york; Novant Health in Charlotte, North carolina; and 67 other locations."
What is the background of Daratumumab in regards to other medical research?
"The first Daratumumab clinical trial was completed in 2004 at the Saint Joseph Regional Medical Center-Mishawaka. To date, there have been a total of 375 completed clinical trials worldwide. There are presently 368 live clinical trials underway; many of these out of Indianapolis, Indiana."
Who would be an eligible candidate to participate in this clinical research?
"This clinical trial is for patients with multiple myeloma who are between 18 and 79 years old. The researchers conducting this study need to enroll around 214 people in total."
How many individuals are in the experimental group for this clinical research?
"That is correct. The clinical trial, which was initially posted on April 26th, 2019 and updated November 3rd, 2020, is looking for 214 patients at 67 different locations."
Does this research study consider patients that are 20 or older to be eligible?
"According to the information available, this trial is for patients aged 18-79. Out of the 1221 trials posted, 56 are for patients younger than 18 while the remaining are for those 65 and older."
Share this study with friends
Copy Link
Messenger